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Abstract
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Traumatic spinal cord injury (SCI) has widespread physiological effects beyond the disruption of
sensory and motor function, notably the loss of normal autonomic and cardiovascular control.
Injury at or above the sixth thoracic spinal cord segment segregates critical spinal sympathetic
neurons from supraspinal modulation which can result in a syndrome known as autonomic
dysreflexia (AD). AD is defined as episodic hypertension and concomitant baroreflex-mediated
bradycardia initiated by unmodulated sympathetic reflexes in the decentralized cord. This
condition is often triggered by noxious yet unperceived visceral or somatic stimuli below the
injury level and if severe enough can require immediate medical attention. Herein, we review the
pathophysiological mechanisms germane to the development of AD, including maladaptive
plasticity of neural circuits mediating abnormal sympathetic reflexes and hypersensitization of
peripheral vasculature that collectively contribute to abnormal hemodynamics after SCI. Further,
we discuss the systemic effects of recurrent AD and pharmacological treatments used to manage
such episodes. Contemporary research avenues are then presented to better understand the relative
contributions of underlying mechanisms and to elucidate the effects of recurring AD on
cardiovascular and immune functions for developing more targeted and effective treatments to
attenuate the development of this insidious syndrome following high-level SCI.
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1. Introduction
In addition to motor and sensory deficits, traumatic spinal cord injury (SCI) causes a
constellation of interrelated autonomic and cardiovascular abnormalities. Cardiovascular
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complications secondary to SCI are among the leading causes of mortality and morbidity in
this population, underscoring the necessity to understand and properly manage resultant
comorbidities (Cragg et al., 2013; Garshick et al., 2005; Myers et al., 2007; Sabre et al.,
2013). In humans, SCI at or above the sixth thoracic (T6) spinal cord segment often results
in the development of a potentially life-threatening syndrome called autonomic dysreflexia
(AD). AD is clinically defined as acute hypertension generated by unmodulated sympathetic
reflexes below the injury level that is often accompanied by baroreceptor-mediated
bradycardia, which provides short-term control of blood pressure (Karlsson, 1999). In
response to hypertension, the baroreflex system lowers blood pressure by reducing heart rate
and decreasing activity of vasoconstrictor sympathetic preganglionic neurons (SPN) located
throughout the thoracolumbar spinal cord that regulate peripheral vascular resistance.
However, while vagal parasympathetic innervation of the heart remains intact after SCI, the
disruption of descending vasomotor pathways to SPN produces an incomplete compensatory
decrease in peripheral vascular resistance so that hypertension persists until the triggering
stimulus is removed (see section 3.1).

Author Manuscript

Typically, AD is precipitated by noxious visceral or somatic stimulation below the level of
injury that activates a massive sympathetic reflex causing widespread vasoconstriction.
While the most common triggers are over-distension of the bowel or bladder (Canon et al.,
2015; Lindan et al., 1980; Snow et al., 1978), other noxious stimuli including skin
lacerations, ingrown toenails, pressure sores, tight clothing and certain medical procedures
such as bladder catheterization and cystometry are also reported to cause AD (reviewed in
Karlsson, 1999). During an episode of AD, arterial blood pressure can reach devastating
levels, with systolic values as high as 325 mmHg (McBride et al., 2003), exemplifying that
AD is a hypertensive crisis that requires immediate medical attention (Muzumdar, 1982;
Showkathali et al., 2007; Verghese, 1989). Severe cases that do not receive rapid and
appropriate treatment can have serious consequences such as hypertensive encephalopathy,
stroke, cardiac arrest, seizure and even death (Bjelakovic et al., 2014; Colachis et al., 1997;
Eltorai et al., 1992;Fausel et al., 2014; Jain et al., 2013; Valles et al., 2005). Bouts of AD can
arise multiple times daily due to the noxious yet unperceived afferent stimulation produced
by normal, intermittent filling of the bladder and bowels (Fougere et al., 2016; Hubli et al.,
2015; Popok et al., 2016). In light of this, it is perhaps not surprising that eliminating AD is
one of the highest priorities of the SCI population, based on a large national survey
(Anderson, 2004) which reported that both quadriplegics and paraplegics prioritize the
recovery of bowel/bladder function and elimination of AD over regaining walking
movements, highlighting the need for research strategies to mitigate the development of AD
altogether.

Author Manuscript

In this review, we provide a clinical description of AD along with its pharmacological
management, and discuss the underlying pathophysiological changes that contribute to such
dangerous, episodic hypertension after high-level SCI. We further describe recent studies
revealing body-wide disturbances that result from chronic recurring episodes of AD,
including vascular, cardiac and immunological dysfunctions. Contemporary research
strategies will be considered to understand more comprehensively the underlying
mechanisms, the full physiological impact of this syndrome that typically occurs multiple
times daily, and potential therapeutic approaches to abrogate its development.
Auton Neurosci. Author manuscript; available in PMC 2019 January 01.
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2. Clinical Description of AD
2.1. Who is at risk for developing AD?
The T6 spinal segment is critical to the development of AD (Lindan et al., 1980;Mathias et
al., 1988; Snow et al., 1978), as damage at or above this level interrupts descending
modulation of the thoracolumbar SPN that regulate vasomotor tone, notably in the extensive
splanchnic vascular bed (Blackmer, 2003; Gao et al., 2002). These vessels are innervated by
the splanchnic nerves arising from the T5-T12 levels (Loukas et al., 2010) and receive
approximately 25% of the cardiac output (Greenway et al., 1974; Rowell, 1990), which can
have a large influence on total peripheral resistance and blood pressure. There are, however,
uncommon reports of AD occurring after lesions below T6 but the magnitude of
hypertension and changes in heart rate tend to be relatively mild since some degree of
control over splanchnic sympathetic outflow remains intact (Moeller et al., 1973).

Author Manuscript

Not all individuals with SCI at or above the T6 level develop AD, with the prevalence
reported between 48% and 91% (Curt et al., 1997; Lindan et al., 1980; Snow et al., 1978).
This discrepancy is likely attributed to differences in the completeness of SCI, time elapsed
since injury, and differences in the criteria used to confirm the presence of AD used among
studies (Furusawa et al., 2011). Indeed, the clinical definition of AD is somewhat
inconsistent (see section 2.2). Interestingly, AD has been documented in cases of nontraumatic abnormalities of the spinal cord such as intramedullary astrocytoma (Furlan et al.,
2003) and multiple sclerosis (Kulcu et al., 2009), indicating that disruption of descending
vasomotor pathways in any manner may contribute to the development of this syndrome.
2.2. Characteristic features of AD

Author Manuscript

The magnitude of hypertension required to be considered AD varies across studies. Snow et
al. (1978) classified AD in adults as an increase of 40 mmHg systolic blood pressure
whereas Popok et al. (2016) defined AD as an increase of 20 mmHg systolic blood pressure.
Others (Lindan et al., 1980) diagnosed AD as a sudden rise in both systolic and diastolic
blood pressure of any magnitude. Veteran’s Affairs guidelines recommend that AD in adults
is considered following abrupt elevation in systolic blood pressure of 20–40 mmHg above
baseline, whereas in pediatric SCI an increase of 15–20 mmHg systolic pressure warrants
consideration (Canon et al., 2015; Consortium for Spinal Cord, 2002).

Author Manuscript

In addition to elevated blood pressure, individuals with an acute episode of AD can
experience a diverse set of symptoms including debilitating headache, sweating, flushing of
the skin above the injury level, piloerection, stuffy nose, blurred vision and anxiety
(Karlsson, 1999). While these symptoms are not simultaneously present in all cases,
headache and sweating above the lesion occurs 88% of the time (Lindan et al., 1980).
Although the classical definition of AD is acute hypertension coincident with bradycardia
(Erickson, 1980; Guttmann et al., 1947; Trop et al., 1991), the importance of heart rate in the
diagnosis of AD is a matter of controversy. Lindan et al. (1980) reported an equal incidence
of bradycardia and tachycardia (increase in heart rate) in documented cases of AD, whereas
others report that tachycardia is more common (Hickey et al., 2004; Kewalramani, 1980;
Scott et al., 1978). Whether an episode of AD is concomitant with an increase or decrease in
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heart rate may depend on the injury level (Collins et al., 2006; Karlsson, 1999; Krassioukov
et al., 2003). As suggested by Karlsson (1999), activation of sympathetic circuits in the
spinal cord below a cervical injury may propagate rostrally towards cardiac-innervating SPN
(i.e., T1-T4), explaining why tachycardia is frequently observed during AD. However, the
correlation between injury level and the direction of heart rate change during episodes of AD
has not been formally investigated.
2.3 Temporal development of AD after injury

Author Manuscript

AD most often presents in the chronic phase of SCI, with a majority of cases first occurring
3–6 months after injury in humans (Lindan et al., 1980). While it may also occur in earlier
stages of injury, the incidence of early AD is relatively low, with only 5.7% of individuals
with SCI above T6 having clinically documented AD within the first month post-injury
(Krassioukov et al., 2003). Though uncommon, the manifestation of AD in the early stage of
injury is significant considering that treatment of acute, high-level SCI often includes
pressor agents to help combat the profound hypotension associated with such injuries
(reviewed in Ploumis et al., 2010). In cases of acute AD occurring within days of injury,
systolic blood pressure as high as 210 mmHg has been reported (Silver, 2000), suggesting
that concurrent vasopressor support may compound damage during episodic hypertension.

Author Manuscript

In experimental SCI, the development of telemetric monitoring techniques, along with the
advent of computer algorithms capable of processing large amounts of hemodynamic data,
have allowed for detailed analysis of the temporal development of AD in conscious animals
(Laird et al., 2006; Mayorov et al., 2001; Rabchevsky et al., 2012; West et al., 2015). In both
rats and mice with high-thoracic SCI, spontaneous AD triggered by naturally occurring
stimuli emerges in a biphasic pattern with a transient surge of events occurring within the
first week, followed by a gradual rise in frequency beginning around 2-weeks post-injury
(Rabchevsky et al., 2012; West et al., 2015; Zhang et al., 2013). Moreover, the magnitude of
change in systolic pressure during these events increases over time (West et al., 2015). These
observations generally correspond to the development of AD in humans, where the initial
disruption to descending vasomotor pathways allows for early AD (Krassioukov et al., 2003)
before maladaptive changes in viscerosympathetic circuitry associated with more frequent
and severe cases occur during the more chronic stages (West et al., 2015). Recent
capabilities of screening ambulatory blood pressure recordings for daily AD events in
humans (Hubli et al., 2014; Popok et al., 2016) will enable detailed analyses of the temporal
progression of this syndrome in humans, as well as the efficacy of drugs to reduce the
frequency or magnitude of recurrent AD.

Author Manuscript

3. Mechanisms contributing to AD
3.1. Loss of supraspinal control over sympathetic preganglionic neurons
Within the intact nervous system, supraspinal vasomotor neurons residing in the
paraventricular nucleus, rostral ventrolateral medulla, rostral ventromedial medulla, caudal
raphe nuclei and A5 cell group (Calaresu et al., 1988; Chalmers et al., 1994; Hosoya et al.,
1991; Jansen et al., 1995; Llewellyn-Smith, 2009; Strack et al., 1989; Sved et al., 2001) send
projections to the intermediolateral cell column (IML), which is comprised of spinal nuclei
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containing sympathetic preganglionic neurons (SPN) that extends throughout the T1-L2
segments (Pyner et al., 1994; Tang et al., 1995; Zagon et al., 1993). These supraspinal
neurons modulate the tonic firing of SPN which, in turn, send projections to the peripheral
sympathetic chain ganglia or directly to the adrenal medulla (see Figure 1). The sympathetic
ganglia act as the final sympathetic effector cells and innervate blood vessels throughout the
body, whereas stimulation of the adrenal medulla secretes epinephrine and norepinephrine
(NE) into the circulation. Together, this provides both direct and indirect control of blood
vessel diameter and peripheral resistance to facilitate hemodynamic homeostasis (reviewed
in Thomas, 2011).

Author Manuscript

After high-level SCI, the descending autonomic pathways responsible for supraspinal
modulation of SPN become interrupted, reducing sympathetic tone below the injury
(Stjernberg et al., 1986) and leaving SPN under the control of spinal influences alone. In the
initial “spinal shock” phase of injury, which can last for weeks in humans (Ditunno et al.,
2004), this loss of descending control manifests as significantly reduced blood pressure and
depression of sympathetic reflexes (Frankel et al., 1972). Over time, however, plasticity of
SPN and reorganization of spinal circuitry create a hyper-excitable state that contributes to
the aberrant reflex activation of SPN in response to afferent stimulation (see Figure 1)
(Krassioukov et al., 2002;Llewellyn-Smith et al., 2001; Rabchevsky, 2006). Because of the
interruption to descending modulatory pathways, which would normally inhibit the SPN
during hypertension via the baroreflex (Guyenet et al., 1981), AD persists until the stimulus
is withdrawn.
3.2 Synaptic reorganization of sympathetic preganglionic neurons (SPN)

Author Manuscript

The damage to descending vasomotor pathways caused by SCI leaves many SPN partially
denervated, causing a number of histological and functional changes in these neurons in both
the human and rat (Krassioukov et al., 1999; Krassioukov et al., 1995; Krassioukov et al.,
1996). Whereas SPN activity is normally regulated by a confluence of supraspinal and
intraspinal inputs, their ongoing activity after complete SCI depends solely on the influence
of spinal sympathetic interneurons (Schramm, 2006). Spinally derived sources of input to
SPN include interneurons residing in laminae V, VII and X (Cabot et al., 1994; Cano et al.,
2001; Clarke et al., 1998; Deuchars et al., 2001;Deuchars et al., 2015; Joshi et al., 1995;
Tang et al., 2004a). While there are no direct synaptic inputs to SPN from primary afferents,
it is thought that sensory neurons can influence the SPN via such spinal interneurons
(Laskey et al., 1988; Schramm, 2006). The integration of supraspinal and intraspinal inputs
on SPN is complex and involves both monosynaptic and polysynaptic pathways (reviewed in
Deuchars et al., 2015).

Author Manuscript

After experimental T4 spinal cord transection in adult rats, profound morphological changes
occur to SPN within the IML below the lesion. Within 3 days of injury, the dendritic length
and diameter of SPN soma decrease dramatically in response to the degeneration of
terminals with supraspinal origins (Llewellyn-Smith et al., 2001). By two-weeks, however,
the somatic size and dendritic arbor of SPN appears normal again (Krassioukov et al., 1996;
Krenz et al., 1998a). These dynamic changes in gross SPN morphology correspond
temporally with the evolution of cardiovascular dysfunction in rats with high-level SCI,
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where pronounced resting hypotension occurs in the first days, followed by a gradual
increase in basal blood pressure and the appearance of recurrent AD by two weeks postinjury (Laird et al., 2006; Mayorov et al., 2001; Rabchevsky et al., 2012; West et al., 2015).
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While atrophied SPN regain a normal morphology in the weeks after injury, experimental
evidence suggests that a radical reorganization of synaptic inputs controlling their activity
occurs. Weaver et al. (1997) demonstrated altered expression patterns of GAP-43 (growth
associated protein-43), a marker of reactive sprouting, in both mature axons and growth
cones in close apposition to SPN caudal to a complete mid-thoracic transection weeks after
injury. Because of the complete transection model used and absence of degenerating
supraspinal axons in the IML after 7 days, the source of these GAP-43 immunoreactive
axons was limited to spinal neurons below the injury, suggesting reorganization of
intraspinal sympathetic circuits that may contribute to the exaggerated sympathetic reflex
during an AD event. Llewellyn-Smith et al., (2001) also observed a switch in the ratio of
synapses on SPN containing glutamate or γ-aminobutyric acid (GABA), indicating a shift in
the balance of excitatory and inhibitory influences, respectively. Specifically, Transection
caused a decrease in the percentage of glutamatergic inputs versus an increase in the
percentage of GABAergic inputs on SPN in the IML at the T8 spinal level after two-weeks,
implying a predominantly inhibitory synaptic integration. While this observation is
consistent with the resting hypotension and reduced sympathetic outflow seen after SCI,
how this relates to the intense sympathetic outbursts that occur in response to noxious
visceral stimulation is uncertain. Recent work by Huang et al. (2016) indicates that complete
high-thoracic (T2) spinal cord transection in rats causes GAB A neurotransmission to
convert from an inhibitory to excitatory role in nociceptive circuits. While the influence of
SCI on GABAergic regulation of SPNs was beyond the scope of this work, it provides
evidence that GABAergic inputs onto SPN may provide excitatory drive after SCI
(Rabchevsky, 2006).

Author Manuscript

An alternative explanation may be that glutamatergic synapses on SPN are the predominate
input recruited by noxious visceral stimulation. It has been documented that glutamatergic
signaling through both NMDA and AMPA receptors is important for the initiation of AD in
response to noxious colorectal distension (CRD) (Maiorov et al., 1997). Ueno et al. (2016)
recently demonstrated that chemogenetic silencing of Vglut2+ (vesicular glutamate
transporter 2) interneurons after T3 SCI suppressed anti-inflammatory sympathetic reflexes
related to AD (see section 5.2). This is further supported by studies testing the anti-epileptic
and neuropathic pain medication gabapentin (GBP) as an experimental treatment for AD
(Rabchevsky et al., 2011). GBP is known to inhibit pre-synaptic glutamate release by
binding to the a251 subunit of voltage-gated calcium channels (Coderre et al., 2005; Coderre
et al., 2007; Gee et al., 1996; Shimoyama et al., 2000) and has been shown to reduce both
the magnitude and frequency of AD in rats with complete Transection, specifically after
acute but not chronic administration (Rabchevsky et al., 2011; Rabchevsky et al., 2012).
Notably, however, the site(s) of action and mechanism(s) through which GBP mitigates AD
remains uncertain. It is feasible that GBP acts by reducing glutamatergic transmission at the
level of both primary afferents entering the spinal cord as well as glutamatergic spinal
interneurons synapsing with SPN. GBP has also been reported to inhibit excitatory
synaptogenesis both in-vitro and in-vivo by blocking the binding of synaptogenic
Auton Neurosci. Author manuscript; available in PMC 2019 January 01.

Eldahan and Rabchevsky

Page 7

Author Manuscript

thrombospondin proteins to the a251 subunit (Eroglu et al., 2009). This suggests that GBP
may work to reduce aberrant excitatory synapse formation in viscerosympathetic circuits
after SCI. However, the short 2–3 hour half-life of GBP in rats (Radulovic et al., 1995;
Vollmer et al., 1986) likely explains why once daily GBP treatment is insufficient to
significantly reduce the frequency of spontaneous AD in the hours following administration;
and likely insufficient to alter putative synaptic formation (Rabchevsky et al., 2012). Further
studies into the synaptic mechanisms controlling SPN during noxious stimulation, as well as
the precise means through which GBP mitigates AD may help identify novel therapeutic
targets for prophylactically preventing the development of this syndrome.
3.3 Primary afferent sprouting

Author Manuscript

Intraspinal sprouting of primary afferent nociceptive fibers is also thought to contribute to
the development of AD. After experimental SCI, the central arbors of unmyelinated c-fiber
afferents expressing calcitonin gene-related peptide (CGRP), a marker of nociceptive fibers,
sprout into the dorsal horn caudal to the injury (Hou et al., 2009; Krenz et al., 1998b). The
extent of CGRP+ fiber sprouting into the lumbosacral spinal cord correlates with the
magnitude of AD elicited by noxious CRD (Cameron et al., 2006; Krenz et al., 1999),
suggesting that enhanced sprouting of nociceptive fibers increases reflex activation of SPN
through propriospinal “relay” neurons (Figure 1, see section 3.4). Increased CGRP+ fiber
density becomes apparent two weeks after experimental injury (Hou et al., 2009; Krenz et
al., 1998b), a time at which AD develops reliably in spinal rats (Krassioukov et al., 1995;
Laird et al., 2006). Importantly, increased CGRP+ fiber sprouting in the dorsal horn is also
seen in the chronic stages of human SCI, and in one case has been associated with a welldocumented history of AD (Ackery et al., 2007).

Author Manuscript
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The sprouting of c-fibers appears to be primarily dependent on nerve growth factor (NGF)
signaling. After transection or contusion SCI, resident neurons and glia upregulate the
expression of intraspinal NGF rostral and caudal to the lesion (Bakhit et al., 1991; Brown et
al., 2004). Blockade of NGF signaling through intrathecal delivery of anti-NGF antibodies
for two-weeks after T4-transection SCI effectively mitigates injury-induced sprouting of
CGRP+ fibers throughout the spinal cord. Furthermore, animals receiving anti-NGF therapy
had less severe AD in response to noxious CRD (Krenz et al., 1999), although this treatment
did not abolish it completely. Cameron et al. (2006) used a proof-of-principle approach to
overexpress NGF in the cord after T4-transection using adenovirus injections into either the
T13/L1 or L6/S1 spinal levels innervating the distal colon and found that the pressor and
bradycardic responses to CRD were significantly exacerbated. Conversely, injured cords
injected with adenovirus encoding semaphorin 3a, a specific chemorepellant for both cfibers and sympathetic fibers (Tang et al., 2004b), had significantly diminished pressor and
bradycardic responses during CRD. Such exacerbations or ameliorations were significantly
correlated with increased or decreased CGRP+ fiber sprouting, respectively.
3.4 Propriospinal plasticity
Plasticity of ascending lumbosacral propriospinal fibers that relay pelvic sensory
information rostrally towards SPN in the thoracic cord is also thought to contribute to the
development of AD. There is compelling evidence for functional plasticity of propriospinal
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interneurons which comprise spinal sympathetic circuits after transection SCI in the rat.
Krassioukov et al. (2002) investigated the response of sympathetically-correlated
interneurons to both noxious and innocuous stimuli hours following T3 transection (acute)
as well as after one month (chronic). In the chronic but not acute stage of injury,
interneurons whose electrical activity was cross-correlated with that of simultaneously
recorded renal sympathetic nerve activity were excited by noxious CRD and cutaneous
pinching, as well as non-noxious brushing of the skin caudal to the injury. This seminal
study showed that in the weeks after injury, plasticity occurs within somatosensory relay
neurons that influence the activity of SPN.
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This electrophysiological evidence was supported histologically following anterograde
tracer injections into the lumbosacral cord after complete T4-transection which significantly
increased labeling of ascending propriospinal fibers originating in the dorsal gray
commissure (DGC), notably found in juxtaposition to thoracic SPN labeled with Fluorogold
(Hou et al., 2008). The DGC is a region in which pelvic visceral afferents terminate and
send relay projections rostrally toward supraspinal targets (Al-Chaer et al., 1996; Hosoya et
al., 1994; Matsushita, 1998; Pascual et al., 1993; Vizzard, 2000). Hou et al. (2008) found
that a single session of prolonged, intermittent CRD performed two weeks after injury
caused enhanced neuronal activation throughout the lumbosacral DGC, as indicated by
increased expression of the immediate early gene c-fos in comparison to sham animals in
which intact descending modulation prevents such expression. It remains unclear, however,
whether the DGC neurons project directly to SPN or whether they project to excitatory
interneurons to indirectly modulate the excitability of SPN (Rabchevsky, 2006).
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Collectively, these findings support a model of AD in which plasticity of ascending
propriospinal fibers, in conjunction with sprouting of primary afferents, creates an
amplification of afferent stimuli below the injury such that noxious inputs are more likely to
activate SPN to initiate unmodulated sympathetic reflexes resulting in an episode of AD
(Figure 1). Previous technical limitations made it difficult to directly test the
neuroanatomical basis of the AD reflex in live animals. However, with the recent
development of elegant genetic and chemogenetic silencing techniques (Kinoshita et al.,
2012; Stachniak et al., 2014; Zhu et al., 2014), it may now be feasible to directly assess the
role of specific populations of ascending propriospinal neurons in conveying lumbosacral
afferent input to rostral segments containing cardiovascular SPN (Figure 1, see section 6).
3.5 Peripheral adrenergic hypersensitivity

Author Manuscript

In addition to maladaptive plasticity of viscerosympathetic circuitry, there is also evidence of
peripheral changes responsible for the exaggerated pressor response to afferent stimulation.
In quadriplegics, resting blood pressure and plasma catecholamine levels are both
significantly lower than in intact subjects (Mathias et al., 1976). This is consistent with the
observation that sympathetic outflow below the lesion is lower both acutely and chronically
after SCI (Mathias et al., 1979; Wallin et al., 1984), which would be expected to produce
lower concentrations of circulating catecholamines (Goldstein et al., 1983). However, it has
been demonstrated that the vasomotor response to intravenously infused NE is enhanced in
quadriplegics with a documented history of AD. Specifically, by measuring the diameter of
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the dorsal foot vein before and after local intravenous administration of NE, Arnold et al.
(1995) found that the concentration of NE required to induce a 50% reduction in resting
vessel diameter was significantly lower in tetraplegics compared to normal controls (1.6
mg/min vs. 10.9 ng/min). Similarly, Krum et al. (1992b) found that the dose of intravenously
infused phenylephrine (a peripheral α1-adrenergic receptor agonist) required to produce a
pressor response of 20 mmHg is significantly lower in functionally complete quadriplegics
compared to normal individuals. Furthermore, Krum et al. (1992a) reported that even modest
increases in plasma NE during bladder cystometry after high-level SCI were sufficient to
produce a significant pressor response greater than 20 mmHg systolic. Taken together, these
studies indicate that SCI promotes hypersensitivity of the vasculature to catecholamines
released through aberrant, unmodulated sympathetic reflexes, and that this
hypersensitization may contribute to the severity of episodic hypertension after SCI.
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There is indication that peripheral sensitization following SCI is limited to the vasculature
caudal to the lesion and not within rostral vascular beds in which central sympathetic control
remains intact. Following T4 transection in rats, Rummery et al. (2010) found evidence of
enhanced neurovascular transmission in the saphenous artery which receives sympathetic
outflow from the lower thoracolumbar cord. However, SCI-related neurovascular
potentiation was not seen in the median artery which receives sympathetic outflow from the
cord rostral to the lesion. Brock et al. (2006) similarly found that T4 transection in rats leads
to increased neurovascular transmission within the mesenteric vasculature, with perivascular
nerve stimulation producing five-fold increased contractions of mesenteric arteries seven
weeks after SCI. This increased reactivity of mesenteric arteries was blunted by the
adrenergic antagonist prazosin, further implicating that peripheral hypersensitization is
secondary to changes in adrenergic transmission after injury. While the mechanism of this
phenomenon is not fully known, Brock et al. (2006) suggest that decreased norepinephrine
reuptake may be a contributing factor. Alternatively, Al Dera et al. (2012) report that
complete SCI in rats also alters L-type calcium channels, with their activation playing a
larger role in smooth muscle contraction of tail arteries isolated after injury. Whether or not
these two mechanisms are unique to specific vascular beds caudal to the lesion remains
unclear.
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Consistent with the hypothesis that SCI causes enhanced adrenergic sensitivity in peripheral
vasculature, Lee et al. (2016) demonstrated increased protein expression of the α1adrenergic receptor in the femoral artery of rats after T10 spinal contusion. Furthermore, this
increased receptor expression corresponded to an enhanced pressor response and
vasoconstriction of isolated femoral arteries in response to phenylephrine stimulation.
Whether or not the time-course of these changes corresponds to the timeline over which AD
develops in rodents or humans remains unknown. Moreover, it is unclear whether these
findings are applicable to AD since this syndrome does not develop after T10 contusion SCI.
Although there is compelling evidence that peripheral sensitization is important in the
pathophysiology of AD, many questions remain regarding the underlying cellular processes
and time-course over which adrenergic hyper-responsiveness develops, as well as the relative
contribution compared to central maladaptive plasticity discussed.
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4. Clinical management of AD
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A variety of non-pharmacological and pharmacological strategies can be used to treat AD.
Since AD often resolves once the inciting stimulus is removed, the current standard of care
recommends identifying and eliminating the inciting factors, when possible, before
pharmacological approaches are considered (Consortium for Spinal Cord, 2002). Immediate
measures involve assessment of resting arterial pressure and monitoring for other symptoms
associated with AD (see section 2.2). If hypertension is observed, it is advised to move
patients into an upright position to facilitate the lowering of arterial pressure through
hydrostatic redistribution of blood to the lower extremities. This postural maneuver causes a
reduction of blood pressure in high-level SCI patients (Krassioukov et al., 2006), although
the efficacy to alleviate hypertension specifically during AD has not yet been formally
investigated (Krassioukov et al., 2009). Since filling of the bladder and impaction of the
bowel are the most common triggers of AD (Lindan et al., 1980), bladder voiding or bowel
care routines should next be considered along with a general inspection for other possible
sources of noxious stimulation such as pressure sores, tight clothing and skin laceration.
Given that blood pressure can fluctuate rapidly in patients with AD, it is important to
monitor blood pressure every 2–5 minutes for resolution or exacerbation of hypertension
during physical examination (Consortium for Spinal Cord, 2002).

Author Manuscript

While some cases of AD are mild and resolve relatively easily, more severe cases can
produce profound levels of hypertension and have no readily identifiable cause.
Furthermore, it may be difficult to identify and remove the triggering stimuli, particularly for
individuals with high thoracic and cervical injuries who have limited dexterity and mobility.
Therefore, a variety of drugs and medical procedures have been employed for the control of
AD, primarily through managing hypertension. Some of the most common remedies are
briefly discussed below.
4.1 Nitrates

Author Manuscript

Organic nitrates, such as nitroglycerine paste, are currently the most commonly prescribed
medications for mitigating acute episodes of AD (Braddom et al., 1991; Caruso et al., 2015).
Nitrates are a class of drugs that are converted to or release nitric oxide (NO), an
endogenous molecule that induces smooth muscle relaxation in the vasculature (Moncada et
al., 1993). For acute episodes of AD, it is recommended to apply 2% nitroglycerin paste
onto the skin above the level of SCI (Braddom et al., 1991). Vasodilation and subsequent
reduction of blood pressure occurs rapidly after transdermal application and the paste can be
wiped off once the therapeutic effect has been achieved (Grobecker, 1990). Moreover, a
variety of oral and transdermal patch preparations are available and easy for patients and
caregivers to administer. In severe cases of AD that are difficult to control, notably in a
clinical setting, intravenous sodium nitroprusside may also be used to rapidly resolve
hypertension (Valles et al., 2005).
4.2 Nifedipine
Nifedipine is an L-type calcium (Ca2+) channel blocker that reduces the influx of Ca2+ into
vascular smooth muscle cells, leading to a reduction in peripheral resistance and
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consequently blood pressure. Despite few controlled clinical trials, nifedipine has been
widely used to treat AD in SCI patients (Braddom et al., 1991; Caruso et al., 2015; Dykstra
et al., 1987; Esmail et al., 2002; Krassioukov et al., 2009; Thyberg et al., 1994). In a survey
of clinicians with extensive experience treating AD, Braddom et al., 1991) found that
nifedipine was the most commonly prescribed agent to manage minor or severe symptoms of
AD. More recently, nitrates have become slightly more prominent than nifedipine in treating
minor or severe episodes of AD (Caruso et al., 2015), likely stemming from safety concerns
regarding the use of nifedipine during hypertensive crises because it may overshoot the
therapeutic drop in blood pressure and cause severe hypotension and ischemia (Chobanian et
al., 2003). Although there are no formal descriptions in the literature of adverse effects
related to the use of nifedipine specifically for AD, it is possible that it may reduce arterial
pressure below the range for critical renal, cerebral and cardiac vascular beds to autoregulate
their perfusion, particularly since many with AD are predisposed to resting and orthostatic
hypotension (Furlan et al., 2008).
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4.3 Prazosin
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The adrenergic receptor antagonist, prazosin, is another drug used to treat AD (Krum et al.,
1992c; Phillips et al., 2015). Prazosin is an antihypertensive agent that works by specifically
blocking α1-adrenergic receptors located on peripheral vasculature (Cavero et al., 1980).
Unlike other hypertension medications, prazosin has little effect on cardiac function or
resting blood pressure (Jaillon, 1980), making it safer to use in patients with chronic
hypotension. Krum et al. (1992c) reported that, compared to placebo treatment, twice daily
prazosin significantly decreased the magnitude of hypertension and severity of secondary
symptoms during AD caused by a variety of genitourinary and colorectal stimuli. More
recently, Phillips et al. (2015) reported that prazosin reduced the magnitude of hypertension
during AD during sperm retrieval procedures involving penile vibrostimulation, which is a
well-documented cause of AD. Collectively, research on the use of prazosin indicates that it
may be useful as a prophylactic treatment for AD triggered by a variety of iatrogenic stimuli
(Krum et al., 1992c; Phillips et al., 2015) .
4.4 Botulinum Toxin
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Conservative pharmacological approaches are not always effective, and some individuals
require more aggressive treatments (Krassioukov et al., 2009). One such treatment is
botulinum toxin (BTX), a neurotoxin derived from Clostridium botulinum that suppresses
neuromuscular transmission by cleaving synaptic proteins required for neurotransmitter
exocytosis (reviewed in Dolly, 2003). Due to its ability to temporarily cause detrusor muscle
paralysis by preventing parasympathetic post-ganglionic acetylcholine release, delivery of
BTX into the detrusor muscle has been used to treat bladder dysfunction secondary to SCI,
such as neurogenic detrusor overactivity (NDO) (Dykstra, 2003; Dykstra et al., 1988;
Orasanu et al., 2013; Schurch et al., 2005). As these conditions disrupt normal micturition
and can lead to noxious distension of the bladder, they are associated with the occurrence of
AD. While there have been no large-scale clinical trials for BTX as a prophylactic treatment
of AD, there is indication that this could be a safe and tenable approach to minimize AD
associated with bladder dysfunction and certain medical procedures such as cystoscopy.
Schurch et al. (2000) reported a disappearance of AD caused by bladder voiding in a small
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subset of patients receiving BTX injections into the detrusor muscle to treat neurogenic
bladder, though the duration of this improvement was not specified. Recently, Fougere et al.
(2016) conducted a small clinical trial specifically to assess the efficacy of intradetrusor
injections of BTX to reduce bladder-related AD and observed a decrease in the severity of
AD during cystometric filling of the bladder. Moreover, ambulatory blood pressure
recordings revealed a decrease in the frequency of daily bladder-related AD for at least one
month, accompanied by an increase in quality of life measures. Such reports indicate that
BTX treatment may be a safe and potentially long-lasting means of prophylactically treating
bladder-related AD. Notably, the duration of effect after BTX treatment is limited due to a
combination of compensatory sprouting of peripheral nerve terminals and the gradual
recovery of synaptic proteins necessary for neurotransmitter release (Dolly, 2003). While the
duration of detrusor paresis is approximately 9 months (Schurch et al., 1996), it remains
unknown how long intradetrusor BTX treatment can provide relief of AD.
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In addition to temporary paralysis of bladder smooth muscle, there is also evidence that
BTX treatment reduces AD by modulating sensory transmission into the spinal cord.
Apostolidis et al. (2005) reported that intradetrusor injections of BTX in patients with NDO
caused a decrease in the expression of both purinoceptors (P2X3) and capsaicin receptors
(TRPV1) in sensory fibers innervating the bladder, and that this decrease was correlated
temporally with a significant improvement in bladder function. These receptors are involved
in bladder nociception (Birder et al., 2002; Cockayne et al., 2000), suggesting that decreased
afferent signaling contributes to the improvement in urodynamic function after BTX
treatment. In an experimental model, Elkelini et al. (2012) instilled BTX into the bladder of
rats after T4-transection and observed a significant reduction in the magnitude of AD
induced by bladder distension during cystometry, which was associated with reduced NGF
expression in the bladder and sensory neurons in the dorsal root ganglia. As NGF regulates
c-fiber density in the bladder (Schnegelsberg et al., 2010), it is also possible that BTX
reduces bladder-related AD by decreasing the innervation or distribution of nociceptive
fibers. Notably, intradetrusor BTX treatment has also been used to alleviate refractory AD in
a pediatric SCI patient (Lockwood et al., 2016).

5. Systemic effects of recurrent AD
5.1 Cardiovascular Changes
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Emerging evidence suggests that the recurrence of AD, which can occur more than 40 times
a day for some individuals (Hubli et al., 2015), adversely affects multiple physiological
systems over time. Alan et al. (2010) demonstrated that repeated instances of AD after
experimental SCI exacerbate injury-induced peripheral vascular dysfunction. Isolated
mesenteric arteries from rats which underwent 30-minutes of continuous CRD daily for twoweeks after T3 transection SCI had a more pronounced vasoconstrictor response to
phenylephrine (an α1-adrenergic agonist) compared to arteries from animals with SCI only.
This suggests that injury-induced adrenergic hypersensitization, which itself is a mechanism
involved in the etiology of AD (see section 3.5), is exacerbated by repeated instances of AD
and may help explain why the severity of AD increases over time (West et al., 2015). If this
is the case, it should be possible to dampen the temporal increase in AD severity by
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pharmacologically controlling adrenergic hypersensitization. However, as discussed in
section 3.5, the cellular processes leading to adrenergic hyper-responsiveness have yet to be
elucidated.
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Repetitive surges in blood pressure from recurrent AD may also induce maladaptive
structural changes in peripheral vasculature (West et al. (2013). Vascular remodeling is a
dynamic process that responds to changes in shear stress from normal hemodynamic
fluctuations as well as hypertensive disease (Baeyens et al., 2015; Schiffrin, 2004; Silver et
al., 2006). While SCI alone is associated with changes in vascular structure, this is believed
to be an adaptation to the decreased metabolic demands of atrophied tissue below the injury
(Olive et al., 2003). The hypothesis that blood pressure fluctuations from recurrent AD cause
further remodeling of peripheral vasculature requires additional study, particularly since
structural changes to resistance vessels, such as alterations in the ratio of wall thickness/
lumen diameter, are strongly associated with cardiovascular disease (Rizzoni et al., 2003).
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Deleterious changes in cardiac function are also associated with daily repeated bouts of
experimental AD. West et al. (2016) investigated the effects of recurrent AD on cardiac
structure and function in rats following T3 transection. Beginning 2-weeks after injury, rats
received 60-minutes of repetitive CRD daily for 4 weeks. In-vivo echocardiography revealed
that animals with daily induced AD (SCI-AD) had diminished basal contractility and their
hearts developed significantly lower left ventricular pressure with a slower rate of ventricular
contraction. These alterations in cardiac mechanics were accompanied by a dampened
inotropic response to β-adrenergic stimulation during isoproterenol challenge in the SCI-AD
group compared to SCI alone, despite no differences in β-adrenergic receptor expression.
Taken together, this data suggests that recurrent AD leads to aberrant cardiac mechanics,
which may be due to desensitization of adrenergic receptors in the heart. Notably, these
experimental findings were corroborated with clinical data which indicated a relationship
between the number of daily AD events and impaired cardiac mechanics in a small sample
of humans with mid-cervical SCI (C4-C8). As suggested by the authors (West et al., 2016),
this consequence of recurrent AD may also contribute to the increased risk of cardiovascular
disease in people with SCI (Cragg et al., 2013; Garshick et al., 2005).
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In addition to peripheral vasculature, there are emerging reports of associations between AD
and cerebrovascular function. Phillips et al. (2016b) found that high-thoracic SCI in rats
causes maladaptive changes in middle cerebral artery (MCA) structure and function. Seven
weeks after T3 transection, ex-vivo analysis of MCA revealed decreased vessel compliance
and diminished vascular reactivity to vasoconstrictive 5-hydroxytryptamine. The functional
changes in MCA preparations were seen in conjunction with increased collagen deposition
and wall thickness, suggesting that arterial stiffening and structural remodeling after SCI
may impair cerebral autoregulation. Considering that T3 transection in rats reliably causes
AD to develop within two weeks, and given the seven-week duration of this study, it is likely
that recurrent AD contributed to these findings. Potential changes in cerebrovascular
function may help explain cognitive dysfunction which has been documented after highlevel SCI (Davidoff et al., 1990; Phillips et al., 2014; Wecht et al., 2013). Phillips et al.
(2016a) provided preliminary data suggesting that cerebral autoregulation is capable of
maintaining sufficient blood flow to the brain during mild and slowly evolving episodes of
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AD, though it remains unknown if the cerebral vasculature can respond appropriately during
more severe and rapidly occurring episodes. Ultimately, it will be important for future
studies to determine whether recurrent AD causes structural and functional modifications to
peripheral and cerebral vasculature since these maladaptations have been proposed to
contribute to cardiovascular and cognitive dysfunction after SCI (Phillips et al., 2016b;
Wecht et al., 2013).
5.2 Immunomodulatory effects of AD
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In addition to cardiovascular anomalies, AD is linked to aberrant functioning of the immune
system (Ueno et al., 2016; Zhang et al., 2013). Compared to the general population, people
with chronic SCI have a weakened immune system capacity (Campagnolo et al., 1994;
Iversen et al., 2000) and are more susceptible to lethal infections such as pneumonia
(Brommer et al., 2016). This phenomenon, known as spinal cord injury-induced immune
depression syndrome (SCI-IDS) (Riegger et al., 2007), is dependent on the level of SCI,
with injuries above the level of the major sympathetic outflow being associated with more
severe immunosuppression (Brommer et al., 2016; Campagnolo et al., 1997; Iversen et al.,
2000; Lucin et al., 2007; Zhang et al., 2013). Iversen et al. (2000) collected blood and bone
marrow samples from individuals with SCI and observed diminished lymphocyte activity
and impaired proliferation of hematopoietic progenitor cells, particularly in tetraplegics with
mid-cervical injuries. Similarly, Lucin et al. (2007) found that T3 but not T9 transection in
mice causes a loss of splenocytes and B cells in association with enhanced levels of splenic
NE and blood cortisol levels.
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In intact subjects, the immune system is modulated by the hypothalamic-pituitary-adrenal
axis (HPA) and sympathetic nervous system (SNS) (reviewed in Irwin et al., 2011). In
response to physical or psychological stress, the anterior pituitary gland releases
adrenocorticotropic hormone to stimulate the release of glucocorticoids (GCs) from the
adrenal cortex into the blood. There is also evidence for direct neural innervation of the
adrenal cortex by SPN (Engeland et al., 2005), suggesting that sympathetic activity during
AD may also promote GC release. GCs subsequently bind to the intracellular glucocorticoid
receptor in leukocytes to alter the transcriptional programming and limit inflammatory
responses (reviewed in Rhen et al., 2005). Additionally, activation of the SNS modulates the
immune system through the release of NE directly into lymphoid tissues, where it binds to
β2-adrenergic receptors on a variety of immune cells, including lymphocytes and
macrophages. Like GCs, NE can have immunosuppressive effects on a variety of immune
cells, including B and T lymphocytes, by activating intracellular signaling cascades such as
the cyclic adenosine monophosphate (cAMP) pathway. Ultimately, the result of such
stimulation is to shunt cellular activity away from a pro-inflammatory state (reviewed in
Lorton et al., 2015).
Because of the immunosuppressive role of SNS stimulation, it is thought that SCI-IDS is
caused by heightened sympathetic activity and catecholamine release during recurrent bouts
of AD. Zhang et al. (2013) reported a causal link between AD and chronic
immunosuppression. The temporal development of AD in mice with T3 transection SCI
corresponded to an elevated level of circulating GCs and accumulation of NE within the
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spleen, along with a profound loss of greater than 50% of splenic leukocytes by 5-weeks
post-injury. Compared to sham operated or low thoracic (T9) SCI mice which do not
develop AD, those with spontaneously occurring AD measured telemetrically and quantified
with a computer detection algorithm had a limited capacity to produce antibodies after
injection of immunogenic ovalbumin. Additionally, this immunodeficiency was exacerbated
by experimentally inducing AD with repeated bouts of noxious CRD. The
immunosuppressive effects associated with established AD were reversed after treating
injured mice with a cocktail of a selective β2-adrenergic receptor antagonist and a GC
receptor antagonist, concluding that immunosuppression after T3 SCI in mice is caused by
AD-related elevations in NE and GC. Notably, however, this treatment cocktail was not
reported to alter the occurrence of AD. These experimental findings in mice were
corroborated with data from a mid-cervical SCI patient showing that tapping of the abdomen
overlying the urinary bladder, which stimulated an episode of AD, caused an increase in
catecholamine release with a concomitant reduction in lymphocyte proliferation (Zhang et
al., 2013). More recently, Ueno et al. (2016) used an inducible chemogenetic silencing
approach in mice with T3 SCI to inhibit glutamatergic interneurons thought to facilitate
reflex activation of SPN innervating the spleen during AD. After silencing these neurons
daily for 2-weeks, the quantity of splenic B and T cells was restored to pre-injury levels.
Together, these studies may explain why people with high-level SCI, many of whom
experience AD, have increased susceptibility to a variety of infectious diseases, and further
implies that controlling or preventing AD is essential for overall well-being.
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Importantly, the immunomodulatory effects of recurrent AD may only be a contributing
factor to SCI-IDS rather than the primary driver. For example, direct sympathetic
innervation of the bone marrow (Bjurholm et al., 1988; Denes et al., 2005) is thought to help
regulate hematopoiesis and immune function in the normal, uninjured state (reviewed in
Jung et al., 2017). Therefore, dysregulated activity of decentralized sympathetic fibers
innervating bone marrow following SCI may also contribute to SCI-IDS. Moreover, it is well
documented that SCI leads to decreased bone density as a result of diminished gravitational
load (Biering-Sorensen et al., 1990; Zehnder et al., 2004). As the bone marrow is a major
site of hematopoiesis, it is possible that bone atrophy after SCI compromises the
hematopoietic niche, which may help to explain the reduced immune cell production seen
after injury (Iversen et al., 2000). The relative contribution of these potential mechanisms
warrants future investigation.

6. Emerging research strategies
Author Manuscript

Important questions remain regarding the underlying mechanisms responsible for episodic
AD that develops after SCI. While strong correlative evidence supports a role in maladaptive
plasticity of lumbosacral primary afferents and ascending propriospinal neurons, the relative
contribution of these modified pathways to the AD syndrome is unclear. Recently developed
genetic and chemogenetic neuronal silencing techniques should allow future investigations
aimed at dissecting the precise role of these distinct neuroanatomical pathways. For
example, Kinoshita et al. (2012) injected a complimentary set of viral vectors into regions of
the spinal cord containing the terminals and soma of propriospinal neurons thought to be
critical for the execution of dexterous hand movements. In their model, a highly efficient
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retrogradely transported lentiviral vector carrying enhanced tetanus toxin (HiRET-eTeNT)
under the control of the tetracycline-responsive element was injected into the spinal
segments containing the terminals of their target neurons. In addition, a second adenoassociated viral (AAV) vector carrying a reverse tetracycline transactivation sequence (AAVrtTAV) was injected into the spinal cord segment containing the cell bodies of those same
neurons. With this approach, it was possible to silence neurons by inducing the expression of
tetanus toxin through systemic delivery of doxycycline. Notably, only the neurons which
were doubly infected with both HiRET-eTeNT and AAV-rtTAV were silenced, providing a
reversible and spatially targeted method for investigating the role of specific neural
pathways. Based on such an approach, it is potentially feasible to doubly infect and silence
ascending propriospinal relay neurons which originate in the lumbosacral cord that project
rostrally towards thoracic SPN to directly test their contribution to AD induced through
stimulation of lumbosacral afferents (see Figure 1). As discussed in section 5.2, Ueno et al.
(2016) employed a novel chemogenetic silencing approach to prevent the development of
SCI-IDS associated with AD by blocking neurotransmission of glutamatergic spinal
interneurons, though it is unknown whether this approach would also ameliorate
hemodynamic changes during AD. Moreover, this method silenced all glutamatergic
interneurons in the injected regions (T5-T7) and, therefore, does not allow for the precise
dissection of specific intraspinal pathways.
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Alternatively, a recent report by Iyer et al. (2016) demonstrated the ability to silence specific
nociceptive primary afferents using a chemogenetic method in which AAV carrying the
engineered inhibitory hMD4(Gi) DREADD receptor (designer receptor exclusively activated
by a designer drug) was injected directly into the sciatic nerve. Upon activation with the
highly specific ligand clozapine-n-oxide (CNO), the hMD4(Gi) receptor hyperpolarizes
neurons through induction of the G-protein inward-rectifying potassium channel
(Armbruster et al., 2007). They demonstrated that intraperitoneal injection of clozapine-noxide (CNO) significantly increased mechanical and thermal nociceptive thresholds in the
foot pads of animals with DREADD infected afferents. Because the genetic and
chemogenetic silencing methods discussed here have distinct ligand-receptor interactions, it
may be possible within a single animal to serially silence propriospinal relay neurons and
primary afferents to directly investigate their contributions to both spontaneous and CRDinduced AD.
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In addition to further mechanistic studies, it will also be important to fully elucidate the
systemic effects of recurrent AD. The metabolic consequences of sporadic, uncontrolled
fluctuations in catecholamines and GCs released during AD are not well known. As
suggested by Karlsson (1999), frequent daily bouts of AD accompanied with such abnormal
surges in GCs and catecholamines may contribute to the high reported incidence of
metabolic abnormalities in persons with SCI (Duckworth et al., 1980; Gorgey et al., 2014;
Maruyama et al., 2008; Yekutiel et al., 1989). Considering that GC and catecholamines have
a number of effects on energy metabolism in various tissues throughout the body, including
the liver, spleen, pancreas, adipose tissue and skeletal muscle (reviewed in Barth et al., 2007;
Vegiopoulos et al., 2007), it is possible that recurring AD predisposes or exacerbates the
development of metabolic disease, such as insulin resistance and dyslipidemia. In support of
this, Bluvshtein et al. (2011) reported that postprandial insulin resistance is present in
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tetraplegics with cervical SCI, but not in paraplegics with thoracic SCI that preserves some
level of supraspinal control over sympathetic outflow. Moreover, manual percussion of the
abdomen overlying the bladder in people with high-thoracic or cervical SCI was found to
activate lipolysis in tissues below the injury level in association with increased blood
pressure and catecholamine release (Karlsson et al., 1997). Whether a relationship exists
between the magnitude and frequency of AD and the incidence of insulin resistance or
abnormal lipid metabolism has not yet been formally investigated.

7. Conclusions
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AD can have a significant impact on the quality of daily living and, if not treated properly
and timely, this hypertensive syndrome can have deleterious cardiophysiological and
systemic consequences. The most common treatment paradigms involve vasoactive drugs
intended to resolve the acute hypertensive crises rather than preventing them from occurring,
though some evidence suggests that prazosin and botulinum toxin may provide prophylactic
management of AD associated with normal and iatrogenic urogenital stimulation. While
well documented, the intracellular signaling processes underlying adrenergic
hypersensitization in the context of AD are unknown. Recent methodological advances
should allow for more detailed investigation into the relative contribution of specific
propriospinal neurons and primary afferent fibers to this aberrant viscerosympathetic reflex
after SCI. The widespread physiological consequences of recurrent AD, which can happen
dozens of times daily, have only recently been investigated. Animal models and clinical data
indicate that repeated episodes of AD exacerbate peripheral adrenergic hypersensitization,
suppress immune function, compromise cardiac mechanics, and potentially alter
cerebrovascular and cognitive function. However, the potential effects of recurrent AD on
peripheral and central vasculature structure, as well as widespread metabolism have only
begun to be investigated. In light of recent data describing profound systemic effects of
chronic AD, it is increasingly important to develop more targeted therapies capable of
preventing the development of this syndrome and its associated maladies altogether in order
to improve quality of lives for individuals with SCI who are predisposed to this syndrome.
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Glossary of acronyms
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SCI

spinal cord injury

AD

autonomic dysreflexia

SCI-IDS

spinal cord injury-induced immune depression syndrome

SPN

sympathetic preganglionic neurons

IML

intermediolateral cell column
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NE

norepinephrine

BTX

botulinum toxin

NDO

neurogenic detrusor overactivity

NGF

nerve growth factor

GABA

gamma-aminobutyric acid

GBP

gabapentin

CRD

colorectal distension

SNS

sympathetic nervous system

HPA

hypothalamic pituitary axis

GC

glucocorticoid

DREADD

designer receptor exclusively activated by designer drug

CNO

clozapine-n-oxide

DGC

dorsal gray commissure

CGRP

calcitonin gene related peptide

NMDA

N-methyl-D-aspartate receptor

AMPA

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
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Highlights
•

Autonomic dysreflexia (AD) is defined as episodic hypertension and
concomitant baroreflex-mediated bradycardia initiated by unmodulated
sympathetic reflexes in the decentralized cord.

•

Herein, we review the pathophysiological mechanisms underlying the
development of AD, including maladaptive plasticity of neural circuits
mediating abnormal sympathetic reflexes and hypersensitization of peripheral
vasculature that collectively contribute to abnormal hemodynamics after SCI.

•

Contemporary research avenues are presented to elucidate the effects of
recurring AD on cardiovascular and immune functions for developing more
targeted and effective treatments to attenuate the development of AD.
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Figure 1.
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Diagrammatic representation of the neuroanatomical circuitry thought to be involved in
autonomic dysreflexia triggered by pelvic visceral stimulation, as well as potential neuronal
pathway silencing paradigms. Descending vasomotor fibers (blue) originating in the
brainstem and hypothalamus modulate the tonic activity of sympathetic preganglionic
neurons (SPN; red) throughout the intermediolateral cell column (IML) in the thoracolumbar
spinal cord. After complete spinal cord injury at or above the T6 segment, SPN which
innervate the adrenal medulla and blood vessels below the injury are segregated from
descending control pathways, allowing for unrestrained sympathetic reflex activity that leads
to hypertension. Injury further leads to maladaptive sprouting of both primary afferent cfibers (purple) and ascending propriospinal tracts (green) originating in the lumbosacral
dorsal gray commissure (DGC). These ascending “relay” neurons are thought to convey
sensory information from the bladder and colon (i.e., distension) rostrally towards SPN.
Emerging neuronal silencing techniques may allow for investigations into the role of specific
neuroanatomical pathways involved in AD. One example might be to employ double
infection of ascending lumbosacral propriospinal neurons with the HiRET-eTeNT vector
(red syringe), which is retrogradely transported (dotted black lines) from nerve terminals in
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the IML to lumbosacral DGC also infected with AAV-rtTAV vector (blue syringe).
Doxycycline-induced silencing of these neurons could then allow for direct investigation
into their roles in facilitating AD during pelvic visceral stimulation.
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